Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients

INTRODUCTION: The antiviral drug favipiravir has been shown to have in vitro antiviral activity against severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2). In this study, we investigated the clinical benefits and initiation of favipiravir treatment in patients with non-severe coronavirus-d...

詳細記述

保存先:
書誌詳細
出版年:J Infect Chemother
主要な著者: Fujii, Satoshi, Ibe, Yuta, Ishigo, Tomoyuki, Inamura, Hirotoshi, Kunimoto, Yusuke, Fujiya, Yoshihiro, Kuronuma, Koji, Nakata, Hiromasa, Fukudo, Masahide, Takahashi, Satoshi
フォーマット: Artigo
言語:Inglês
出版事項: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052467/
https://ncbi.nlm.nih.gov/pubmed/33902990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jiac.2021.04.013
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料